MARKET

VRTX

VRTX

Vertex Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

269.02
+0.54
+0.20%
Opening 09:30 05/25 EDT
OPEN
269.70
PREV CLOSE
268.48
HIGH
269.70
LOW
268.57
VOLUME
53.64K
TURNOVER
14.05M
52 WEEK HIGH
292.75
52 WEEK LOW
176.36
MARKET CAP
68.80B
P/E (TTM)
28.35
1D
5D
1M
3M
1Y
5Y
Vertex Pharmaceuticals Receives Composite Rating Upgrade
On Tuesday, Vertex Pharmaceuticals got an upgrade for its IBD SmartSelect Composite Rating from 94 to 96. Keep an eye out to see if VRTX stock sees more buying action from institutional investors. The new Composite score means the company is now outperform...
Investor's Business Daily · 1d ago
What 5 Analyst Ratings Have To Say About Vertex Pharmaceuticals
Over the past 3 months, 5 analysts have published their opinion on Vertex Pharmaceuticals (NASDAQ:VRTX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will t...
Benzinga · 2d ago
Why Is Catalyst Biosciences (CBIO) Stock Soaring 170% Today?
Investor Place · 2d ago
Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2022
 
Benzinga · 2d ago
Vertex initiated with a market perform at Leerink on validating pipeline, need for M&A
Leerink has initiated Vertex Pharmaceuticals (NASDAQ:VRTX) with a market perform rating saying that the biotech needs to validate its pipeline and pursue more M&A to diversify. The firm has a
Seekingalpha · 2d ago
Catalyst Biosciences Stock More Than Doubles After Assets Sale To Vertex
Benzinga · 2d ago
Why Catalyst Biosciences Shares Are Skyrocketing Today
Catalyst Biosciences Inc (NASDAQ: CBIO) shares are trading higher by 180.26% at $1.06 after the company announced it sold its complement portfolio for $60 million.
Benzinga · 2d ago
Vertex buys protease assets from Catalyst Bio
The clinical-stage biotech Catalyst Biosciences (NASDAQ:CBIO) announced on Monday that cystic fibrosis drugmaker, Vertex Pharmaceuticals (VRTX) signed an asset purchase and sale agreement with the company to acquire a group
Seekingalpha · 2d ago
More
No Data
Learn about the latest financial forecast of VRTX. Analyze the recent business situations of Vertex Pharmaceuticals Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 28 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

21.43%Strong Buy
50.00%Buy
28.57%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average VRTX stock price target is 293.15 with a high estimate of 368.00 and a low estimate of 240.00.
High368.00
Average293.15
Low240.00
Current 268.24
EPS
Actual
Estimate
0.901.792.683.58
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 1.38K
Institutional Holdings: 256.06M
% Owned: 100.12%
Shares Outstanding: 255.76M
TypeInstitutionsShares
Increased
398
16.34M
New
143
2.35M
Decreased
358
11.87M
Sold Out
97
1.78M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.81%
Pharmaceuticals & Medical Research
-0.69%
Key Executives
Chairman/Executive Director
Jeffrey Leiden
President/Chief Executive Officer/Director
Reshma Kewalramani
Chief Financial Officer/Executive Vice President
Charles Wagner
Chief Operating Officer/Executive Vice President
Stuart Arbuckle
Executive Vice President/Chief Scientific Officer
David Altshuler
Executive Vice President
Carmen Bozic
Executive Vice President
Amit Sachdev
Executive Vice President
Bastiano Sanna
Executive Vice President
Ourania Tatsis
Senior Vice President/Chief Accounting Officer
Kristen Ambrose
Senior Vice President/General Counsel
Joy Liu
Lead Director/Independent Director
Bruce Sachs
Independent Director
Sangeeta Bhatia
Independent Director
Lloyd Carney
Independent Director
Alan Garber
Independent Director
Terrence Kearney
Independent Director
Yuchun Lee
Independent Director
Margaret Mcglynn
Independent Director
Diana Mckenzie
No Data
No Data
About VRTX
Vertex Pharmaceuticals Incorporated is a biotechnology company. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO. It offers its products to treat people with CF who have specific mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. Its CFTR correctors, such as lumacaftor, tezacaftor, and elexacaftor, help CFTR proteins reach the cell surface. It offers pipeline of small molecule medicines in other serious diseases where it has insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases.

Webull offers kinds of Vertex Pharmaceuticals Incorporated stock information, including NASDAQ:VRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VRTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VRTX stock methods without spending real money on the virtual paper trading platform.